STAMPEDE delivers yet again!

Written By Declan Murphy

23rd September 2021

Some huge data coming out of #ESMO21 this week! And as ever, the amazing STAMPEDE trial delivers another practice-changing headline grabber. This time it's a focus on so-called "M0 high-risk" patients in STAMPEDE, with clear data showing that the addition of two years of abiratrone acetate to standard of care provides a massive benefit in metastasis-free survival and overall survival.
We are joined today by STAMPEDE co-PI Professor Noel Clarke, Urologist and Professor of Urological Oncology at the Christie NHS Foundation Trust, and Professor Silke Gillessen, Medical Oncologist at the Oncology Institute of Southern Switzerland, and also a STAMPEDE investigator. Silke is also the co-Chair of the fantastic Advanced Prostate Cancer Consensus Conference (APCCC) which we also discuss today (see link for upcoming virtual APCCC in October).
Regular hosts Professor Declan Murphy and Dr Renu Eapen are also joined in studio by Associate Professor Arun Azad, Medical Oncologist at Peter MacCallum Cancer Centre.

Links
GU Cast on YouTube
APCCC upcoming meeting
Silke Gillessen Twitter
APCCC Twitter

 

Or you can enjoy the audio version here

Declan Murphy
Previous

Active surveillance no longer "preferred" management for low-risk prostate cancer? Really NCCN??! Jeez
Next

PSMA PET/CT prior to biopsy?? PRIMARY trial in Eur Urol